Reverse Transcriptase Inhibitors: Mechanism and Role in HIV Treatment

Targeting the Retroviral Life Cycle

Reverse transcriptase inhibitors (RTIs) are a cornerstone of antiretroviral therapy (ART) for HIV-1 and HIV-2. They block the enzyme that allows retroviruses to convert their RNA genome into DNA—a mandatory step for integration into the host chromosome.

Two Classes of RTIs

ClassMechanismExamplesResistance Profile
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs/NtRTIs)Competitive substrate analogs; lack 3'-OH → chain termination after incorporation.Tenofovir (TDF/TAF), Emtricitabine (FTC), Lamivudine (3TC), Abacavir (ABC), Zidovudine (AZT)Common mutations: M184V (FTC/3TC), K65R (TDF), K103N (AZT).
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)Allosteric binding to hydrophobic pocket → conformational change inhibiting polymerase activity.Efavirenz (EFV), Nevirapine (NVP), Rilpivirine (RPV), Doravirine (DOR), Etravirine (ETR)Low genetic barrier; single mutation (K103N, Y181C, G190A) confers high-level resistance to 1st-gen NNRTIs.

Clinical Use

  • First-line ART: 2 NRTIs + 1 INSTI (integrase strand transfer inhibitor) preferred (e.g., BIC/FTC/TAF, DTG/3TC). NNRTI-based regimens are alternatives.
  • Post-Exposure Prophylaxis (PEP): TDF/FTC + DTG or RAL for 28 days.
  • Pre-Exposure Prophylaxis (PrEP): TDF/FTC or TAF/FTC daily; event-driven (2-1-1) for MSM.

Key Points

  • RTIs do not cure HIV; they suppress replication to undetectable levels (<50 copies/mL), preserving immune function and preventing transmission (U=U).
  • Adherence is critical—subtherapeutic levels select for resistance.
  • NRTIs require intracellular phosphorylation; NNRTIs do not.
  • Renally cleared NRTIs (TDF, FTC, 3TC) need dose adjustment for eGFR <50 mL/min.

Reverse transcriptase is also a target for other retroviruses (HTLV-1/2), but clinical use is limited to HIV.

Viral Infections - Related Articles